On Tuesday, Organon & Co. (NYSE: OGN) opened lower -0.57% from the last session, before settling in for the closing price of $17.45. Price fluctuations for OGN have ranged from $10.84 to $23.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -7.62% annually for the last half of the decade. Company’s average yearly earnings per share was noted 3.80% at the time writing. With a float of $256.91 million, this company’s outstanding shares have now reached $257.47 million.
In an organization with 10000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.59%, operating margin of 17.53%, and the pretax margin is 10.32%.
Organon & Co. (OGN) Insider Updates
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Organon & Co. is 0.22%, while institutional ownership is 80.42%. The most recent insider transaction that took place on Feb 22 ’24, was worth 49,939. In this transaction Gen. Counsel & Corp. Secy. of this company bought 2,720 shares at a rate of $18.36, taking the stock ownership to the 15,181 shares.
Organon & Co. (OGN) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted 0.87 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at 1.06) by -0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.49% during the next five years compared to -14.04% drop over the previous five years of trading.
Organon & Co. (NYSE: OGN) Trading Performance Indicators
Check out the current performance indicators for Organon & Co. (OGN). In the past quarter, the stock posted a quick ratio of 1.17. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.70. Likewise, its price to free cash flow for the trailing twelve months is 5.23.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.89, a number that is poised to hit 0.90 in the next quarter and is forecasted to reach 4.54 in one year’s time.
Technical Analysis of Organon & Co. (OGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.78 million. That was inferior than the volume of 2.17 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.33%. Additionally, its Average True Range was 0.42.
During the past 100 days, Organon & Co.’s (OGN) raw stochastic average was set at 1.71%, which indicates a significant decrease from 7.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 9.53% in the past 14 days, which was lower than the 31.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.84, while its 200-day Moving Average is $19.28. However, in the short run, Organon & Co.’s stock first resistance to watch stands at $17.47. Second resistance stands at $17.59. The third major resistance level sits at $17.70. If the price goes on to break the first support level at $17.24, it is likely to go to the next support level at $17.13. Assuming the price breaks the second support level, the third support level stands at $17.01.
Organon & Co. (NYSE: OGN) Key Stats
There are currently 257,171K shares outstanding in the company with a market cap of 4.47 billion. Presently, the company’s annual sales total 6,263 M according to its annual income of 1,023 M. Last quarter, the company’s sales amounted to 1,607 M and its income totaled 195,000 K.
